Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled multiple ascending dose study of oral HPP737 in moderate to severe COPD
CTR20200736Phase 2Completed
- Sponsor
- Hengyi Biopharmaceutical
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HPP737 in chronic obstructive pulmonary disease (COPD), sponsored by Hengyi Biopharmaceutical. Started Dec 2020; status: completed.
02
Drugs
HPP737
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20200736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200736.